Literature DB >> 6133734

Newer antisecretory agents for peptic ulcer.

K W Somerville, M J Langman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6133734     DOI： 10.2165/00003495-198325030-00003

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  79 in total

1.  Inhibition of gastrin secretion by sulpiride treatment in duodenal ulcer patients.

Authors:  R Caldara; M Romussi; C Ferrari
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

2.  Failure of 16-16-dimethyl-prostaglandin E2 to stimulate alkaline secretion in the isolated amphibian gastric mucosa.

Authors:  R Schiessel; J G Allison; A Barzilai; L A Fleischer; J B Matthews; A Merhav; J Simson; W Silen
Journal:  Gastroenterology       Date:  1980-06       Impact factor: 22.682

3.  Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury.

Authors:  A Robert; J E Nezamis; C Lancaster; A J Hanchar
Journal:  Gastroenterology       Date:  1979-09       Impact factor: 22.682

4.  Lack of effect of ranitidine on warfarin action.

Authors:  M J Serlin; R G Sibeon; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

5.  Effect of cimetidine on gastric juice N-nitrosamine concentration.

Authors:  P I Reed; P L Smith; K Haines; F R House; C L Walters
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

6.  Comparison between ranitidine, cimetidine, pirenzepine and placebo in the short term treatment of duodenal ulcer.

Authors:  A Giacosa; R Cheli; F Molinari; M C Parodi
Journal:  Scand J Gastroenterol Suppl       Date:  1982

7.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

8.  Effect of 16,16-dimethyl prostaglandin E2 on the gastric mucosal barrier.

Authors:  J P Bolton; M M Cohen
Journal:  Gut       Date:  1979-06       Impact factor: 23.059

9.  Doxepin in the treatment of duodenal ulcer. An open clinical and endoscopic study comparing doxepin and cimetidine.

Authors:  G S Hoff; T E Ruud; M Tønder; O Holter
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

10.  Treatment of duodenal ulcer with ranitidine, a new histamine H2-receptor antagonist.

Authors:  A Berstad; K Kett; E Aadland; E Carlsen; K Frislid; K Saxhaug; A Kruse-Jensen
Journal:  Scand J Gastroenterol       Date:  1980       Impact factor: 2.423
View more
  3 in total

1.  Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine.

Authors:  P Sikiric; I Rotkvic; S Mise; M Petek; R Rucman; S Seiwerth; V Zjacic-Rotkvic; M Duvnjak; V Jagic; E Suchanek
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.

Authors:  U Klotz; P Arvela; B Rosenkranz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome.

Authors:  Predrag Sikiric; Anita Skrtic; Slaven Gojkovic; Ivan Krezic; Helena Zizek; Eva Lovric; Suncana Sikiric; Mario Knezevic; Sanja Strbe; Marija Milavic; Antonio Kokot; Alenka Boban Blagaic; Sven Seiwerth
Journal:  World J Gastroenterol       Date:  2022-01-07       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.